Responsiveness of impairments and disabilities in Parkinson's disease.

The objective of this study is to evaluate the responsiveness of items of the Activities of Daily Living (ADL) and Motor section of the Unified Parkinson's Disease Rating Scale (UPDRS) in patients with Parkinson's Disease (PD). A standardized Response Mean (SRM) per item was calculated using data of four trials (n=376) that randomised patients with early PD to dopamine agonist (DA) monotherapy or placebo. In the ADL section, the SRMs ranged from -0.04 (no effect) to -0.50 (moderate effect). Hand functions were the most responsive ADL items with 'handwriting' showing the largest response. Self-assessed symptoms were the least responsive. In the Motor section, SRMs ranged from -0.09 to -0.60 with bradykinesia items showing the largest response, especially the item 'finger taps'. The tremor items showed the smallest response, however, rest tremor arms was much more responsive than rest tremor of the head and legs or postural tremor. SRMs in the placebo group ranged from 0.08 to -0.21 in the ADL section and from 0.03 to -0.35 in the Motor section. ADL and motor items have comparable and mostly small effect sizes. The most responsive items are in the ADL section hand functions and in the Motor section bradykinesia items. A more responsive ADL section would omit the self-assessed symptoms and the Motor section would retain only rest tremor arms of the tremor items.

[1]  R. Marconi,et al.  Pergolide monotherapy in the treatment of early PD , 1999, Neurology.

[2]  M H Liang,et al.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. , 1985, Arthritis and rheumatism.

[3]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[4]  L. D. de Witte,et al.  Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. , 1997, Journal of clinical epidemiology.

[5]  J. Hubble,et al.  Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.

[6]  S. Leurgans,et al.  Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Beaton,et al.  Understanding the relevance of measured change through studies of responsiveness. , 2000, Spine.

[8]  S. Leurgans,et al.  Objective changes in motor function during placebo treatment in PD , 2000, Neurology.

[9]  P. Martínez-Martín,et al.  Unified Parkinson's disease rating scale characteristics and structure , 1994, Movement disorders : official journal of the Movement Disorder Society.

[10]  S Fahn,et al.  Freezing of gait in PD , 2001, Neurology.

[11]  A. Bonnet Involvement of Non-Dopaminergic Pathways in Parkinson’s Disease , 2000 .

[12]  A. H. Zwinderman,et al.  Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale , 1994, Movement disorders : official journal of the Movement Disorder Society.

[13]  I Litvan,et al.  Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.

[14]  A. Zwinderman,et al.  Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[15]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[16]  J. Lakke Axial apraxia in Parkinson's disease , 1985, Journal of the Neurological Sciences.

[17]  P. Lachenbruch Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[18]  C. Adler,et al.  Ropinirole for the treatment of early Parkinson's disease , 1997, Neurology.

[19]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[20]  F. Vingerhoets,et al.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.

[21]  R. Elble Tremor and dopamine agonists , 2002, Neurology.

[22]  K. Marder,et al.  Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.

[23]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[24]  Pablo Martínez-Martín,et al.  Patients', doctors', and caregivers' assessment of disability using the UPDRS‐ADL section: Are these ratings interchangeable? , 2003, Movement disorders : official journal of the Movement Disorder Society.

[25]  M Richards,et al.  Interrater reliability of the unified Parkinson's disease rating scale motor examination , 1994, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Walker,et al.  Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[27]  M. Liang,et al.  Comparisons of Five Health Status Instruments for Orthopedic Evaluation , 1990, Medical care.

[28]  G. Stebbins,et al.  Factor structure of the unified Parkinson's disease rating scale: Motor examination section , 1998, Movement disorders : official journal of the Movement Disorder Society.

[29]  Jacob Cohen Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[30]  A. Siderowf,et al.  Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial , 2002, Movement disorders : official journal of the Movement Disorder Society.

[31]  O. Rascol,et al.  A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. , 1998, Clinical neuropharmacology.

[32]  A. Stiggelbout,et al.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.